With a mean follow up of 28 months, only HER2/neu expression at study entry as a continuous variable (HR = 1.125 95% CI: 1.021 – 1.238) and disease stage (HR = 6.34 95% CI 1.30 – 30.82) correlated ...

The HER2/neu 655 A>G polymorphism has been linked to cardiotoxicity risk. This study evaluates the cost-effectiveness of HER2/neu 655 genotyping. Methods: Eighty-eight HER2-positive breast cancer ...

CHICAGO -- Patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan (Enhertu) achieved significant improvements in survival compared with those treated with chemotherapy ...

Panelists discuss how integrating HER2-directed therapies into existing NSCLC decision-making processes presents challenges, focusing on strategies for timely updates as new therapies emerge and ...

With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing the HER2 ...

Among previously treated patients with human epidermal growth factor receptor 2 (HER2, ERBB2)–mutant advanced non-small cell lung cancer (NSCLC), zongertinib has received priority review from the Food ...

Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to ...

The Food and Drug Administration (FDA) has granted accelerated approval to Ziihera ® (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2 ...

A new test for HER2+ breast cancer allows delivery of more personalized treatment, say researchers at the Baylor College of Medicine in Houston. The group developed and validated a multiparameter ...